Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Khammari, Amir, Knol, Anne-Chantal, Nguyen, Jean-Michel, Bossard, Céline, Denis, Marc-Guillaume, Pandolfino, Marie-Christine, Quéreux, Gaëlle, Bercegeay, Sylvain, Dréno, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987883/
https://www.ncbi.nlm.nih.gov/pubmed/24741578
http://dx.doi.org/10.1155/2014/186212
_version_ 1782311946678173696
author Khammari, Amir
Knol, Anne-Chantal
Nguyen, Jean-Michel
Bossard, Céline
Denis, Marc-Guillaume
Pandolfino, Marie-Christine
Quéreux, Gaëlle
Bercegeay, Sylvain
Dréno, Brigitte
author_facet Khammari, Amir
Knol, Anne-Chantal
Nguyen, Jean-Michel
Bossard, Céline
Denis, Marc-Guillaume
Pandolfino, Marie-Christine
Quéreux, Gaëlle
Bercegeay, Sylvain
Dréno, Brigitte
author_sort Khammari, Amir
collection PubMed
description Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P = 0.023) or OS (P = 0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression.
format Online
Article
Text
id pubmed-3987883
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39878832014-04-16 Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival Khammari, Amir Knol, Anne-Chantal Nguyen, Jean-Michel Bossard, Céline Denis, Marc-Guillaume Pandolfino, Marie-Christine Quéreux, Gaëlle Bercegeay, Sylvain Dréno, Brigitte J Immunol Res Clinical Study Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P = 0.023) or OS (P = 0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression. Hindawi Publishing Corporation 2014 2014-01-08 /pmc/articles/PMC3987883/ /pubmed/24741578 http://dx.doi.org/10.1155/2014/186212 Text en Copyright © 2014 Amir Khammari et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Khammari, Amir
Knol, Anne-Chantal
Nguyen, Jean-Michel
Bossard, Céline
Denis, Marc-Guillaume
Pandolfino, Marie-Christine
Quéreux, Gaëlle
Bercegeay, Sylvain
Dréno, Brigitte
Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title_full Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title_fullStr Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title_full_unstemmed Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title_short Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
title_sort adoptive til transfer in the adjuvant setting for melanoma: long-term patient survival
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987883/
https://www.ncbi.nlm.nih.gov/pubmed/24741578
http://dx.doi.org/10.1155/2014/186212
work_keys_str_mv AT khammariamir adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT knolannechantal adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT nguyenjeanmichel adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT bossardceline adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT denismarcguillaume adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT pandolfinomariechristine adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT quereuxgaelle adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT bercegeaysylvain adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival
AT drenobrigitte adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival